IP Library Granted Patent US 11,357,734
Granted Patent B2
US 11,357,734 · App. 17/350,478 · Granted Jun 14, 2022

Pharmaceutical granulations of water-soluble active pharmaceutical ingredients

Inventors: Sami Karaborni (Cupertino, CA); William W. Xiang (Fremont, CA); Daniel M. Canafax (Half Moon Bay, CA); Jia-Ning Xiang (Fremont, CA)
Assignee: XWPHARMA LTD.
A61K9/5073A61K9/0053A61K31/195A61K47/02A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,734
App. No.
17/350,478
Granted
Jun 14, 2022
Kind
B2
Abstract

Granulations with granules having a high loading of an active pharmaceutical ingredient are disclosed. The active pharmaceutical ingredient has a high aqueous water solubility. The granules have a narrow particle size distribution and a smooth exterior surface.

Claims (38)

1. Granules comprising:

greater than 95 wt % of a compound of Formula (2a):

or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (2a) has an aqueous solubility greater than 100 mg/mL;

from 0.1 wt % to 1.0 wt % of a binder; and

from 0.1 wt % to 2.0 wt % of an antistatic agent;

wherein wt % is based on the total weight of the granules; and

wherein the granules are characterized by:

a particle size distribution (PSD) D10 from 50 μm to 150 μm, a D50 from 150 μm to 350 μm, and a D90 from 475 μm to 725 μm, wherein the particle size distribution is determined by laser diffraction or by sieve analysis;

a loss on drying (LOD) from 0.05 wt % to 1.5 wt %, wherein wt % is based on the weight of the granules after drying;

a friability value less than 2 wt %, wherein friability is determined using a sonic sifter; and

a bulk density from 0.50 g/mL to 1.20 g/mL, wherein bulk density is determined according to USP 616, Method I.

2. The granules of claim 1 , wherein the compound of Formula (2a) is characterized by a particle size distribution characterized by a D10 from 1 μm to 3 μm, a D50 from 6.5 μm to 8.5 μm, and a D90 from 15 μm to 17 μm, wherein the particle size distribution is determined by laser diffraction or by sieve analysis.

3. The granules of claim 1 , wherein the compound of Formula (2a) has a specific surface area from 200 m 2 /kg to 1200 m 2 /kg, wherein the specific surface area is determined by laser diffraction.

4. The granules of claim 1 , wherein the compound of Formula (2a) is characterized by a bulk density from 0.1 g/mL to 0.4 g/mL, wherein the bulk density is determined according to USP 616, Method 1.

5. The granules of claim 1 , wherein the granules comprise from 96 wt % to 99.5 wt % of the compound of Formula (2a), wherein wt % is based on the total weight of the granules.

6. The granules of claim 1 , wherein the granules are characterized by a friability less than 1.10 wt %, wherein wt % is based on the total weight of the granules, and the friability is determined using a sonic shifter.

7. The granules of claim 1 , wherein the granules comprise:

from 98 wt % to 99 wt % of the compound of Formula (2a);

from 0.25 wt % to 0.75 wt % of the binder; and

from 0.5 wt % to 1.5 wt % of the antistatic agent,

wherein wt % is based on the total weight of the granules.

8. The granules of claim 1 , wherein the granules consist of:

from 98 wt % to 99 wt % of the compound of Formula (2a);

from 0.25 wt % to 0.75 wt % of the binder; and

from 0.5 wt % to 1.5 wt % of the antistatic agent,

wherein wt % is based on the total weight of the granules.

9. The granules of claim 1 , wherein the binder comprises hydroxypropyl cellulose.

10. The granules of claim 1 , wherein the antistatic agent comprises hydrophilic fumed silica.

11. The granules of claim 1 , wherein the granules comprise a coating.

12. A pharmaceutical composition comprising the granules of claim 1 .

13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises an oral suspension.

14. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises an immediate release formulation.

15. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises a controlled release formulation.

16. The granules of claim 1 , wherein the granules comprise a controlled release coating.

17. The granules of claim 1 , wherein,

the binder comprises hydroxypropyl cellulose; and

the antistatic agent comprises hydrophilic fumed silica.

18. The granules of claim 1 , wherein the granules are characterized by an average sphericity greater than 0.90, wherein sphericity is determined using wet dispersion particle shape methods or by dynamic image analysis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2021
From: KARABORNI, SAMI; XIANG, WILLIAM W.; CANAFAX, DANIEL M.; XIANG, JIA-NING
To: XWPHARMA LTD.
Reel/Frame 056576/0070 →
Continuity (2)
Provisional Application 63040780 · Jun 18, 2020
Related Publication 20210393537A1 · Dec 23, 2021